PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer

被引：0
|
作者：
Metzger-Filho, Otto
Mandrekar, Sumithra
Loibl, Sibylle
Ciruelos, Eva
Gianni, Luca
Lim, Elgene
Miller, Kathy
Huang, Cynthia
Koehler, Maria
Francis, Prue
Valagussa, Pinuccia
Goel, Shom
Prat, Aleix
Goetz, Matthew
Loi, Sherene
Krop, Ian
Carey, Lisa
Lanzillotti, Jane
Winer, Eric
Tripathy, Debu
DeMichele, Angela
机构：
[1] Alliance Fdn Trials, Boston, MA USA
[2] German Breast Grp, Neu Isenburg, Germany
[3] Australia & New Zealand Breast Canc Trials Grp, Newcastle, NSW, Australia
[4] Fdn Michelangelo, Milan, Italy
[5] Pfizer, New York, NY USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-05-07
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The association of higher tumor HER2 load with treatment response to neoadjuvant therapy in HER2 positive breast cancer patients
    Lillemoe, T. J.
    Susnik, B.
    Grimm, E.
    Kang, S-H L.
    Swenson, K. K.
    Krueger, J. L.
    Finkelstein, M. J.
    Tsai, M. L.
    CANCER RESEARCH, 2017, 77
  • [32] EFFICACY OF HER2-TARGETED THERAPY FOR HER2 POSITIVE BREAST CANCER ACCORDING TO HR STATUS
    Murata, T.
    Takahashi, M.
    Hayashida, T.
    Hirose, S.
    Jinno, H.
    Kitagawa, Y.
    BREAST, 2013, 22 : S104 - S104
  • [33] Alternative targeted therapy for early Her2 positive breast cancer
    Harvey, Sandra L.
    Khasraw, Mustafa
    GLAND SURGERY, 2013, 2 (01) : 42 - 45
  • [34] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Elisa Van Raemdonck
    G. Floris
    P. Berteloot
    A. Laenen
    I. Vergote
    H. Wildiers
    K. Punie
    P. Neven
    Breast Cancer Research and Treatment, 2021, 185 : 183 - 194
  • [35] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Van Raemdonck, Elisa
    Floris, G.
    Berteloot, P.
    Laenen, A.
    Vergote, I.
    Wildiers, H.
    Punie, K.
    Neven, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 183 - 194
  • [36] Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial
    Ignatiadis, M.
    Brandao, M.
    Maetens, M.
    Ponde, N.
    Martel, S.
    Drisis, S.
    Veys, I.
    Mazy, S.
    Bollue, E.
    Neven, P.
    Duhoux, F. P.
    Chapiro, J.
    Awada, A. H.
    Besse-Hammer, T.
    Paesmans, M.
    Piccart, M.
    Vuylsteke, P.
    Sotiriou, C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [37] Loss of HER2 expression in HER2-positive breast cancer patients after neoadjuvant therapy
    Sang, Yuting
    Wu, Jiong
    Yang, Benlong
    CANCER RESEARCH, 2022, 82 (04)
  • [38] HER2 as a target for breast cancer therapy
    Tagliabue, Elda
    Balsari, Andrea
    Campiglio, Manuela
    Pupa, Serenella M.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (05) : 711 - 724
  • [39] Multimodal learning predictor of HER2-positive breast cancer therapy response in the randomized PREDIX HER2 trial
    Wang, Kang
    Zhu, Yajing
    Zerdes, Ioannis
    Sifakis, Emmanouil
    Manikis, Georgios
    Salgkamis, Dimitrios
    Tsiknakis, Nikolaos
    Harbers, Luuk
    Crosetto, Nicola
    Bergh, Jonas
    Matikas, Alexios
    Hatschek, Thomas
    Foukakis, Theodoros
    CANCER RESEARCH, 2024, 84 (09)
  • [40] Her2 positive subtype and breast cancer brain metastasis: any effect of anti-Her2 targeted therapy?
    Kadri Altundag
    Journal of Neuro-Oncology, 2017, 135 : 639 - 639
12345